For the quarter ending 2025-09-30, CRMD had -$109,932,741 decrease in cash & cash equivalents over the period. $30,350,728 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 108,562,980 | 40,471,879 |
| Stock-based compensation | 4,065,541 | 6,177,435 |
| Change in right-of-use assets | 103,339 | 79,045 |
| Depreciation | 161,917 | 220,987 |
| Amortization of intangible | 3,628,549 | 103,896 |
| Change in contingent consideration | -2,400,000 | - |
| Change in fair value of equity securities | -3,090,909 | - |
| Deferred income taxes, net | -59,686,802 | - |
| Other, net | -363,230 | - |
| Increase in trade receivables | 87,270,234 | -8,741,948 |
| Increase in inventory | 642,977 | 2,034,903 |
| Increase in prepaid expenses and other assets | -1,108,444 | 1,805,687 |
| Increase (decrease) in accounts payable | 6,499,113 | 4,095,158 |
| Increase in accrued expenses | 54,730,977 | -6,239,674 |
| Decrease in operating lease liabilities | -76,666 | -81,767 |
| Net cash provided by (used in) operating activities | 30,856,502 | 49,728,317 |
| Acquisitions of businesses, net of cash acquired | 310,001,965 | - |
| Investment in equity securities | 5,000,000 | - |
| Purchase of short-term investments | 9,605,591 | 38,272,474 |
| Maturity of short-term investments | 33,792,887 | 17,900,000 |
| Purchase of equipment | 505,774 | 34,122 |
| Net cash (used in) provided by investing activities | -291,320,443 | -20,406,596 |
| Proceeds from sale of common stock from public offering, net | 3,891 | 82,366,709 |
| Proceeds from senior convertible notes | 150,000,000 | - |
| Proceeds from sale of common stock from at-the-market program, net | 0 | 6,761,573 |
| Payment of employee withholding taxes on vested restricted stock units | 464,088 | 1,266,472 |
| Proceeds from exercise of stock options | 1,322,690 | 1,473,324 |
| Payment of debt issuance costs associated with the convertible notes | 282,377 | - |
| Rou financing lease fees | 49,192 | - |
| Net cash provided by financing activities | 150,530,924 | 89,335,134 |
| Foreign exchange effect on cash | 276 | 1,057 |
| Net increase (decrease) in cash and cash equivalents | -109,932,741 | 118,657,912 |
| Cash and cash equivalents at beginning of period | 40,756,138 | - |
| Cash and cash equivalents at end of period | 49,481,309 | - |
CorMedix Inc. (CRMD)
CorMedix Inc. (CRMD)